Last $2.39 USD
Change Today -0.03 / -1.24%
Volume 1.9M
GERN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Thomas Hofstaetter Ph.D.

Independent Director and Chairman of Corporate Development Committee, BioAlliance Pharma
AgeTotal Calculated CompensationThis person is connected to 18 board members in 2 different organizations across 4 different industries.

See Board Relationships
65€9,345

Background*

Dr. Thomas Hofstaetter, Ph.D., served as the President and Chief Executive Officer of VaxInnate, Inc. since March 2010. Dr. Hofstaetter was responsible for Business Development Finance and Human Resources at VaxInnate. Dr. Hofstaetter served as the Chief Operating Officer of VaxInnate, Inc. since December 9, 2009. He served executive roles in research and development, as well as strategy and business development, during postings around the world, including the United ...

Read Full Background

Corporate Headquarters*

149 Commonwealth Drive
Menlo Park, California 94025

United States

Phone: 650-473-7700
Fax: 650-473-7750

Board Members Memberships*

Former Chief Executive Officer and President
2010-Present
Independent Director and Member of Compensation Committee
2012-Present
Independent Director and Chairman of Corporate Development Committee

Education*

MS
Eberhard Karls Universität Tübingen
PhD
Eberhard Karls Universität Tübingen

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

Total Annual Cash Compensation€9,345
Total Calculated Compensation€9,345
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GERN:US $2.39 USD -0.03

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Michael S. Anderson Chief Executive Officer and Director
Flamel Technologies SA
--
George W. Hebard III, M.B.AInterim Principal Executive Officer, Interim Chief Operating Officer and Secretary
Enzon Pharmaceuticals Inc.
$428.5K
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
$590.6K
Peter William Grant Chief Executive Officer and Executive Director
SkyePharma plc
567.0K GBP
William J. Polvino M.D.Chief Executive Officer and President
Veloxis Pharmaceuticals A/S
--
Compensation as of Fiscal Year --.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GERON CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.